JOSEPH RENZI: Open Payments
NPI 1043255003 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,633 in 113 payments from 32 companies in 2025. Trend: 2023 $3,158 · 2024 $3,515 · 2025 $2,633
Food & beverage: $2,633
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $339 |
| Braeburn Inc. | 9 | $289 |
| Novo Nordisk Inc | 13 | $283 |
| ABBVIE INC. | 18 | $229 |
| SHIELD THERAPEUTICS INC | 5 | $205 |
| Kowa Pharmaceuticals America, Inc. | 6 | $174 |
| Aimmune Therapeutics, Inc. | 4 | $102 |
| Astellas Pharma US Inc | 4 | $101 |
| Lundbeck LLC | 4 | $87 |
| Lilly USA, LLC | 3 | $76 |
Products named: BRIXADI, ACCRUFER, FARXIGA, ZORYVE, REXULTI, VRAYLAR, Veozah, ZENPEP.
Industry payments across PA — which companies pay providers there.
